Skip to main content
Journal cover image

Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.

Publication ,  Journal Article
Caixeta, A; Dangas, GD; Mehran, R; Feit, F; Nikolsky, E; Lansky, AJ; Aoki, J; Moses, JW; Steinhubl, SR; White, HD; Ohman, EM; Manoukian, SV ...
Published in: Am Heart J
February 2011

BACKGROUND: The aim of the study was to investigate the incidence and clinical consequences of acquired thrombocytopenia in patients with acute coronary syndromes (ACS) in the ACUITY trial. METHODS: We examined 10,836 patients with ACS randomized to receive heparin plus glycoprotein (GP) IIb/IIIa inhibitor, bivalirudin plus GP IIb/IIIa inhibitor, or bivalirudin monotherapy. RESULTS: Acquired thrombocytopenia developed in 740 (6.8%) patients; mild (100,000-150,000 platelets/mm³), moderate (50,000-100,000 platelets/mm³), and severe (< 50,000 platelets/mm³) developed in 656 (6%), 51 (0.5%), and 33 (0.3%) patients, respectively. Patients with acquired thrombocytopenia, compared with those without, were more likely to develop major bleeding (14% vs 4.3%, P < .0001) at 30 days and had higher rates of mortality (6.5% vs 3.4%, P < .0001) at 1 year. By multivariate analysis, acquired thrombocytopenia was an independent predictor of major bleeding at 30 days (hazard ratio [HR] 1.68, 95% CI 1.04-2.72, P = .03). Moderate and severe acquired thrombocytopenia were predictors of mortality at 1 year (HR 2.89, 95% CI 0.92-9.06, P = .06, and HR 3.41, 95% CI 1.09-10.68, P = .03, respectively). Compared to heparin plus GP IIb/IIIa inhibitor, bivalirudin monotherapy was associated with less declines in platelet count by >25% (7.6% vs 5.6%, P = .0009) and >50% (1.4% vs 0.7%, P = .004) from baseline. CONCLUSIONS: Acquired thrombocytopenia occurs in approximately 1 in 14 patients with ACS treated with antithrombin and antiplatelet medications and is strongly associated with hemorrhagic and ischemic complications. Compared to an anticoagulant regimen including a GP IIb/IIIa inhibitor, administration of bivalirudin monotherapy appears to be associated with less frequent declines in platelet count.

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

February 2011

Volume

161

Issue

2

Start / End Page

298 / 306.e1

Location

United States

Related Subject Headings

  • Triage
  • Thrombocytopenia
  • Prospective Studies
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male
  • Incidence
  • Humans
  • Fibrinolytic Agents
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Caixeta, A., Dangas, G. D., Mehran, R., Feit, F., Nikolsky, E., Lansky, A. J., … Stone, G. W. (2011). Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Am Heart J, 161(2), 298-306.e1. https://doi.org/10.1016/j.ahj.2010.10.035
Caixeta, Adriano, George D. Dangas, Roxana Mehran, Frederick Feit, Eugenia Nikolsky, Alexandra J. Lansky, Jiro Aoki, et al. “Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.Am Heart J 161, no. 2 (February 2011): 298-306.e1. https://doi.org/10.1016/j.ahj.2010.10.035.
Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Am Heart J. 2011 Feb;161(2):298-306.e1.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

February 2011

Volume

161

Issue

2

Start / End Page

298 / 306.e1

Location

United States

Related Subject Headings

  • Triage
  • Thrombocytopenia
  • Prospective Studies
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male
  • Incidence
  • Humans
  • Fibrinolytic Agents
  • Female